Clinical Trial Finder Search Results

About the Fight CRC Clinical Trial Finder

This Trial Finder is a one-stop place to find and learn more about high-impact clinical trials for colorectal cancer patients with advanced colon or rectal cancer. Originally created by the late Dr. Tom Marsilje as a curated spreadsheet of trials, the FightCRC’s Trial Finder is a resource to find research studies that are open in your geography, and for which you may be eligible. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status. The list of trials here is sourced from the ClinicalTrials.gov website and curated with Comments and Helpful Links. The searches can be focused on immunotherapy-centered trials and narrowed to studies enrolling patients who already have received immunotherapies.

Medical Disclaimer

The information contained in this website is not intended to recommend the self management of health problems, medical conditions or wellness. It is not intended to endorse or recommend any particular type of medical treatment, physician or treatment facility. Should any reader have any health care related questions, promptly call or consult your physician or healthcare provider. The information contained in this website should NOT be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider. Fight Colorectal Cancer disclaims any liability based on information provided in this website.

Location

MS status

Recruitment Status

Phase

Drugs

Prior Immunotherapy Allowed

NCT ID

Title key word search

Date Trial Added

From To

View:

Compact Expanded

PDF Excel CSV

NCT ID	Title	Phase	Date Added	Location	Prior IO Allowed	CRC-directed	Status	Drugs	Tags
NCT ID NCT05493683	TitleDisitamab Vedotin Combined With Tislelizumab in Advanced HER2 Positive Colorectal Cancer	Phase Phase 2	Date Added 2022-08-09	Location China,China,China,China,China,China	Prior IO Allowed Yes	CRC-directed Yes	Status Recruiting	Drugs Disitamab vedotin, Tislelizumab	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05491317	TitleA Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid Tumors	Phase Phase 1, Phase 2	Date Added 2022-08-08	Location France	Prior IO Allowed Yes	CRC-directed No	Status Terminated	Drugs Pembrolizumab	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05491083	TitlePembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer	Phase Phase 1, Phase 2	Date Added 2022-08-08	Location Singapore	Prior IO Allowed No	CRC-directed No	Status Recruiting	Drugs Pembrolizumab & ADG106 (Phase Ib), Pembrolizumab & ADG106 (Phase II)	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05487235	TitleA Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors	Phase Phase 1	Date Added 2022-08-04	Location Argentina Australia Brazil Canada Korea, Republic of New Zealand	Prior IO Allowed Yes	CRC-directed No	Status Completed	Drugs Atezolizumab, GDC-1971, Omeprazole	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05482516	TitleEvaluating Novel Therapies in ctDNA Positive GI Cancers	Phase Phase 3	Date Added 2022-08-01	Location District of Columbia, United States New Jersey, United States	Prior IO Allowed No	CRC-directed Yes	Status Recruiting	Drugs Atezolizumab, Bevacizumab, Avastin, Tecentriq	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05480306	TitlePhase 2 Study of DKN-01 in Colorectal Cancer	Phase Phase 2	Date Added 2022-07-29	Location Arizona, United States California, United States Florida, United States Louisiana, United States Maryland, United States Missouri, United States New York, United States North Carolina, United States South Carolina, United States South Dakota, United States Tennessee, United States Washington, United States Wisconsin, United States Germany Korea, Republic of	Prior IO Allowed No	CRC-directed Yes	Status Completed	Drugs Bevacizumab, DKN-01, FOLFIRI, FOLFOX	Tags MSS/ MMRp
NCT ID NCT05479812	TitleDose Escalation Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors	Phase Phase 1	Date Added 2022-07-29	Location Arizona, United States Florida, United States Georgia, United States Illinois, United States Indiana, United States Minnesota, United States New Jersey, United States New York, United States Oregon, United States Texas, United States	Prior IO Allowed Yes	CRC-directed No	Status Recruiting	Drugs Pembrolizumab, WTX-124	Tags MSI-H/ MMRd
NCT ID NCT05464030	TitleAnti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)	Phase Phase 1	Date Added 2022-07-19	Location California, United States Rhode Island, United States Texas, United States Canada Japan South Korea Spain	Prior IO Allowed Yes	CRC-directed Yes	Status Recruiting	Drugs M9140	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05438342	TitleAn Expanded Clinical Study of Triple Therapy for Refractory Solid Tumors That Failed First-line Treatment for Recurrence and Metastasis	Phase Not Applicable	Date Added 2022-06-29	Location China	Prior IO Allowed Yes	CRC-directed No	Status Recruiting	Drugs Chemotherapy，checkpoint immunotherapy, targeted therapy	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05426005	TitleCadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer	Phase Phase 1, Phase 2	Date Added 2022-06-21	Location China	Prior IO Allowed Yes	CRC-directed Yes	Status Recruiting	Drugs Cadonilimab	Tags MSI-H/ MMRd

Showing 91 to 100 of 299 entries